BioNexus Gene Lab Corp (BGLC) Form 10-Q — May 15, 2026
BioNexus Gene Lab Corp (BGLC) reported a 99% year-over-year revenue collapse to $22,842 for Q1 2026, driven by a near-total halt in operations at its Chemrex subsidiary following governance failures. The company recorded a net loss of $543,575 and disclosed a material weakness in internal controls, citing unauthorized transactions by former Chemrex management that led to a $2.94 million demand for repayment. Despite the operational distress, BGLC highlighted strategic capital initiatives, including a $500 million equity purchase agreement with ARC Group International and an effective $20 million ATM facility with Maxim Group.
Key figures
- Revenue
- 22842
- Total Assets
- 9040130
- Cash Position
- 2397977
- Shares Outstanding
- 2417314
- Atm capacity usd
- 20000000
- Fidelion stake percent
- 15
- Atm proceeds to date usd
- 267311
- Fidelion license fee usd
- 2000000
- Chemrex demand amount usd
- 2944000
- Arc facility commitment usd
- 500000000
- Arc commitment shares issued
- 175000
- Bglc shares issued to fidelion
- 392329
Price after filing
Close on the filing date to close N calendar days later (from $1.98). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.